New drug combination treatment for a rare type of blood cancer in young people

Plain-English translation of NCT06124157 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new treatment plan for a rare type of blood cancer called Philadelphia chromosome-positive or ABL-class Philadelphia chromosome-like acute lymphoblastic leukemia. The study combines traditional chemotherapy with (a medication that helps your immune system fight cancer cells) and continuous targeted drugs like or (which target specific cancer cell mutations). The goal is to see if this combination works better and is safer than current standard treatments.

Most patients with this type of leukemia do well with existing treatments, but some still relapse or experience serious side effects. This trial exists to find out whether this new combination—which uses the immune-boosting medication alongside traditional chemotherapy and targeted drugs—can improve survival rates and reduce harmful side effects.

Do you qualify?

You likely qualify if…

you are between 1 and 25 years old (depending on which hospital network enrolls you)
you have been newly diagnosed with Philadelphia chromosome-positive or ABL-class Philadelphia chromosome-like B-cell acute lymphoblastic leukemia
you have not yet received more than 2 weeks of initial chemotherapy
you have a good enough overall health status to handle intensive cancer treatment
your kidney function is adequate enough to receive the study medications safely

You likely don't qualify if…

you have already received more than 2–5 weeks of certain cancer drugs before enrolling
you have severe organ damage, particularly kidney or liver problems
your cancer cells do not express the CD19 marker that the immune-boosting medication targets
you are unable to come to hospital visits regularly for treatment and monitoring

What participation looks like

Participants in this study will receive chemotherapy infusions, take targeted medications ( or ) by mouth continuously, and receive several cycles of as intravenous infusions. You will have frequent hospital visits for treatment, blood tests, and monitoring of side effects over several years. The study will also check how well the cancer responds using special tests that look for remaining cancer cells in your blood.

New drug combination treatment for a rare type of blood cancer in young people

What is this trial?

Do you qualify?

What participation looks like

Trial locations(155 sites)